​

4D Molecular Therapeutics Ownership | Who Owns 4D Molecular Therapeutics?

OverviewForecastRevenueFinancialsChart

4D Molecular Therapeutics Ownership Summary

4D Molecular Therapeutics is owned by 85.79% institutional investors, 2.97% insiders, and 11.25% retail investors. Blackrock is the largest institutional shareholder, holding 9.94% of FDMT shares. Vanguard US Total Market Shares ETF is the top mutual fund, with 3.32% of its assets in 4D Molecular Therapeutics shares.

FDMT Ownership Benchmark

TypeName% Inst% Insiders% Retail
Stock4D Molecular Therapeutics85.79%2.97%11.25%
SectorHealthcare Stocks 50.50%12.33%37.17%
IndustryBiotech Stocks 49.09%12.06%38.85%

Institutional Shareholders

Top Institutional Shareholders by Total Shares

HolderShares% HoldingValue
Blackrock4.90M9.94%$102.79M
Janus henderson group5.25M9.06%$48.87M
Ra capital management5.05M7.42%$67.16M
Blackrock funding, inc. /de4.55M6.68%$60.46M
Goldman sachs group4.26M6.26%$56.64M
Vanguard group3.09M5.51%$23.20M
Novo3.25M4.77%$43.21M
State street2.91M4.28%$38.72M
Bvf inc/il2.88M4.23%$38.29M
T. rowe price investment management2.51M3.69%$33.41M

Top Institutional Shareholders by % of Total Assets

HolderShares% AssetsValue
Acuta capital partners507.80K4.71%$6.75M
Novo3.25M2.51%$43.21M
Propel bio management252.65K1.76%$3.36M
Parkman healthcare partners948.18K1.29%$12.61M
Catalio capital management, lp471.25K1.18%$6.27M
Bvf inc/il2.88M0.98%$38.29M
Diadema partners lp571.11K0.96%$7.60M
Ra capital management5.05M0.58%$67.16M
Persistent asset partners145.59K0.58%$1.94M
Opaleye management334.44K0.40%$4.45M

Top Buyers

HolderShares% AssetsChange
T. rowe price investment management2.51M0.02%2.51M
Adage capital partners gp2.25M0.04%644.05K
Blackrock4.90M0.00%612.35K
Janus henderson group5.25M0.02%611.28K
Diadema partners lp571.11K0.96%571.11K

Top Sellers

HolderShares% AssetsChange
Viking global investors lp---2.93M
Point72 asset management---1.54M
Braidwell lp---1.23M
Federated hermes222.42K0.00%-1.21M
Casdin capital---1.15M

New Positions

HolderShares% AssetsChangeValue
T. rowe price investment management2.51M0.02%2.51M$33.41M
Diadema partners lp571.11K0.96%571.11K$7.60M
Acuta capital partners507.80K4.71%507.80K$6.75M
Norges bank500.82K0.00%500.82K$2.79M
Catalio capital management, lp471.25K1.18%471.25K$6.27M

Sold Out

HolderChange
Innealta capital-4.00
Advisory services network-8.00
Nelson, van denburg & campbell wealth management group-8.00
Root financial partners-11.00
Mai capital management-18.00

Institutional Ownership Trends

DateHoldingsChange %SharesChange %OwnershipChange %Increased PositionChange %Decreased PositionChange %
Jun 30, 20261655.10%58,390,19415.35%851.55%9537.68%38-19.15%
Mar 31, 2026151-2.58%49,527,045-7.29%850.94%68-21.84%4624.32%
Dec 31, 202540-70.59%5,592,450-85.86%90.20%21-69.12%10-77.78%
Sep 30, 202539-65.49%6,758,953-80.69%120.31%21-62.50%11-69.44%
Jun 30, 2025120-4.00%40,390,122-6.26%721.21%5823.40%39-35.00%

Top Mutual Funds Shareholders

HolderShares% HoldingChange
Vanguard US Total Market Shares ETF1.54M3.32%-
Vanguard Total Stock Mkt Idx Inv1.59M3.04%-65.87K
Vanguard Morn Total Stk Mkt Idx Investor1.59M3.04%-65.87K
State Street® SPDR® S&P® Biotech ETF1.58M3.03%3.64K
iShares Russell 2000 ETF1.17M2.24%-20.83K
SPDR® S&P Biotech ETF986.40K2.13%14.03K
Janus Henderson Hrzn Biotec E2 USD904.51K1.73%-79.83K
Janus Henderson Gbl Life Sciences Divers851.19K1.67%851.19K
Janus Henderson Global Life Sciences D840.95K1.61%-2.80K
Polar Capital Healthcare Opports Inc790.16K1.52%-

Recent Insider Transactions

DateNameRoleActivityValue
Aug 17, 2026Bizily Scott Chief Legal OfficerSell$19.95K
Aug 13, 2026Bizily Scott Chief Legal OfficerSell$19.62K
Aug 04, 2026Kirn David See RemarksSell$274.60K
Aug 03, 2026Kirn David See RemarksSell$124.72K
Jul 10, 2026Kirn David See RemarksSell$183.56K

Insider Transactions Trends

DateBuySell
2026 Q3-7
2026 Q2-4
2026 Q1-2
2025 Q4-7
2025 Q3-1

FDMT Ownership FAQ

Who Owns 4D Molecular Therapeutics?

4D Molecular Therapeutics shareholders are primarily institutional investors at 85.79%, followed by 2.97% insiders and 11.24% retail investors. The average institutional ownership in 4D Molecular Therapeutics's industry, Biotech Stocks , is 49.09%, which 4D Molecular Therapeutics exceeds.

Who owns the most shares of 4D Molecular Therapeutics?

4D Molecular Therapeutics’s largest shareholders are Blackrock (4.9M shares, 9.94%), Janus henderson group (5.25M shares, 9.06%), and Ra capital management (5.05M shares, 7.42%). Together, they hold 26.42% of 4D Molecular Therapeutics’s total shares outstanding.

Does Blackrock own 4D Molecular Therapeutics?

Yes, BlackRock owns 9.94% of 4D Molecular Therapeutics, totaling 4.9M shares as of Jun 2024. This represents 0.00% of BlackRock's total assets, with a market value of 102.79M$. In the last quarter, BlackRock increased its holdings by 612.35K shares, a 14.29% change.

Who is 4D Molecular Therapeutics’s biggest shareholder by percentage of total assets invested?

Acuta capital partners is 4D Molecular Therapeutics’s biggest shareholder by percentage of total assets invested, with 4.71% of its assets in 507.8K 4D Molecular Therapeutics shares, valued at 6.75M$.

Who is the top mutual fund holder of 4D Molecular Therapeutics shares?

Vanguard US Total Market Shares ETF is the top mutual fund holder of 4D Molecular Therapeutics shares, with 3.32% of its total shares outstanding invested in 1.54M 4D Molecular Therapeutics shares.

Try Tickergate Pro Free

Customize Everything. 100% Flexibility. Fast and Easy to Use (No code or Excel Needed)

  • Customize your own personal stocks lists, views and charts

  • Choose from hundreds of fields, up to 15 years of history

  • Conduct deep comparison analysis

  • Discover trending investment themes

  • Find your next best investment

  • Research stocks using tools